Monday, November 23, 2015

Pfizer takeover: what is a tax inversion deal and why are they so controversial?

The nature of the merger with Ireland-based Allergan has renewed debate over corporate tax avoidance. Here’s why such deals often meet political opposition

US drugs giant Pfizer is merging with Irish-headquartered Allergan in a record-breaking $155bn (£100bn) deal. It is the largest so-called tax inversion move to date, and will bring huge tax savings to Pfizer as it shifts its headquarters from the US to tax-light Ireland.

Related: Pfizer's $155bn takeover of Allergan set to prompt tax row

Related: Corporate inversion - moving the head office for tax purposes

Continue reading...

from Mergers and acquisitions | The Guardian http://ift.tt/1P3uPzE

No comments:

Post a Comment